AbelZeta Receives FDA IND Clearance for Phase 1b/2 Clinical Trial of C-CAR168 in Progressive Multiple Sclerosis

U.S. Food and Drug Administration (FDA) has cleared AbelZeta’s Investigational New Drug (IND) application to initiate a Phase 1b/2 clinical trial evaluating C-CAR168, an anti-CD20/BCMA bispecific CAR-T, in patients with progressive multiple sclerosis refractory to standard therapy. The post AbelZeta Receives FDA IND Clearance for Phase 1b/2 Clinical Trial of C-CAR168 in Progressive Multiple Sclerosis appeared first on AbelZeta Pharma .